Barclays
MYGN icon

Barclays’s Myriad Genetics MYGN Stock Holding History

Barclays’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-2,700
Closed -$39K – 6021
2020
Q1 		$39K Sell
2,700
-1,600
-37% -$33.8K ﹤0.01% 5367
2019
Q4 		$117K Sell
4,300
-4,200
-49% -$116K ﹤0.01% 5389
2019
Q3 		$243K Sell
8,500
-115,900
-93% -$3.38M ﹤0.01% 4827
2019
Q2 		$3.46M Buy
124,400
+123,000
+8,786% +$3.47M ﹤0.01% 2268
2019
Q1 		$46K Sell
1,400
-600
-30% -$18.3K ﹤0.01% 5936
2018
Q4 		$58K Hold
2,000
– – ﹤0.01% 5396
2018
Q3 		$92K Sell
2,000
-10,300
-84% -$458K ﹤0.01% 5623
2018
Q2 		$460K Sell
12,300
-33,400
-73% -$1.13M ﹤0.01% 4027
2018
Q1 		$1.35M Buy
45,700
+45,500
+22,750% +$1.54M ﹤0.01% 2867
2017
Q4 		$7K Sell
200
-4,700
-96% -$159K ﹤0.01% 6600
2017
Q3 		$177K Sell
4,900
-6,100
-55% -$174K ﹤0.01% 4525
2017
Q2 		$284K Buy
11,000
+5,300
+93% +$113K ﹤0.01% 4059
2017
Q1 		$109K Buy
5,700
+300
+6% +$5.32K ﹤0.01% 4819
2016
Q4 		$90K Buy
5,400
+4,200
+350% +$76K ﹤0.01% 4819
2016
Q3 		$25K Buy
1,200
+1,100
+1,100% +$27.9K ﹤0.01% 5360
2016
Q2 		$3K Sell
100
-8,700
-99% -$302K ﹤0.01% 5863
2016
Q1 		$326K Sell
8,800
-12,800
-59% -$482K ﹤0.01% 3487
2015
Q4 		$929K Sell
21,600
-155,800
-88% -$6.58M ﹤0.01% 2682
2015
Q3 		$6.56M Buy
177,400
+122,400
+223% +$4.34M 0.01% 1197
2015
Q2 		$1.81M Sell
55,000
-14,400
-21% -$490K ﹤0.01% 2301
2015
Q1 		$2.43M Buy
69,400
+30,800
+80% +$1.1M ﹤0.01% 2131
2014
Q4 		$1.31M Sell
38,600
-70,000
-64% -$2.48M ﹤0.01% 2935
2014
Q3 		$4.13M Sell
108,600
-35,500
-25% -$1.32M ﹤0.01% 1966
2014
Q2 		$5.48M Buy
144,100
+80,000
+125% +$2.98M 0.01% 1656
2014
Q1 		$2.18M Sell
64,100
-81,600
-56% -$2.53M ﹤0.01% 2468
2013
Q4 		$2.91M Buy
145,700
+66,300
+84% +$1.68M ﹤0.01% 2302
2013
Q3 		$1.83M Sell
79,400
-1,600
-2% -$45.5K ﹤0.01% 2692
2013
Q2 		$2.18M Buy
+81,000
New +$2.35M ﹤0.01% 2456

Other funds holding MYGN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Barclays's MYGN Position: Q1 2026 in Review

Barclays reduced its Myriad Genetics (MYGN) stake by 78% in Q1 2026, selling an estimated $1.22M and leaving 66,800 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #3472.

Barclays first reported a position in MYGN in Q2 2013 and has held it in 52 quarters since. The position peaked at $10.9M in Q4 2019. 202 funds tracked by Wall St. Rank hold MYGN as of Q1 2026.

  • Barclays held 66,800 shares of Myriad Genetics worth $301K as of Q1 2026.
  • Barclays sold 234,988 Myriad Genetics shares in Q1 2026, an estimated $1.22M.
  • Myriad Genetics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #3472 holding.
  • Barclays first reported a position in Myriad Genetics in Q2 2013 and has held it in 52 quarters since.
  • Barclays's Myriad Genetics position peaked at $10.9M in Q4 2019.
  • 202 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.